ER-Positive Breast Cancer | Data + Perspectives: Clinical Investigators Explore the Current and Future Management of ER-Positive Breast Cancer — A Special Video Supplement
A special video supplement to a CME conference held during the
2019 San Antonio Breast Cancer Symposium featuring expert comments
on the management of ER-positive breast cancer. Featuring
perspectives from Dr Harold J Burstein.
Use of genomic classifiers to inform therapeutic
decision-making for ER-positive localized breast cancer
(00:00)
Prognostic and/or predictive utility of the various genomic
assays for patients with node-negative and node-positive early
breast cancer (03:23)
Implications of the TAILORx intermediate-risk cohort results
for adjuvant treatment for pre- and postmenopausal patients with
localized breast cancer (05:27)
Effects of prolonging adjuvant aromatase inhibitor therapy
beyond 5 years on recurrence and cause-specific mortality
(10:42)
NSABP-B-42: Ten-year results of extended adjuvant endocrine
therapy with letrozole for postmenopausal women with ER-positive
breast cancer who have completed previous adjuvant therapy with an
aromatase inhibitor (AI) (12:28)
Optimizing the use of CDK4/6 inhibitors in the management of
ER-positive metastatic breast cancer (mBC); overall survival
findings and mechanisms of resistance (14:56)
Management of de novo ER-positive, HER2-negative mBC
(18:22)
Choice of endocrine therapy partner for patients with de novo
ER-positive, HER2-negative mBC (21:39)
Approach for patients with mBC and disease progression on an AI
(24:04)
Selection and sequencing of CDK4/6 inhibitors in mBC;
comparison of side-effect profiles (26:40)
Incidence, identification and prognostic significance of PI3K
mutations in patients with ER-positive mBC (31:35)
Results of the Phase III SOLAR-1 trial evaluating
alpelisib/fulvestrant versus fulvestrant alone for patients with
ER-positive, HER2-negative advanced BC with or without a PIK3CA
mutation after disease progression on first-line endocrine therapy;
FDA approval for breast cancer with a PIK3CA mutation and current
clinical role (33:27)
Spectrum, frequency and severity of toxicities observed with
alpelisib (36:09)
Clinical experience with everolimus in mBC; potential for its
use after disease progression on a CDK4/6 inhibitor (39:07)
Biologic rationale for evaluation of the Bcl-2 inhibitor
venetoclax in ER-positive mBC (40:54)
Overview of the novel HER2-directed agents trastuzumab
deruxtecan and tucatinib for HER2-positive mBC (44:00)
Dual targeted approach for patients with ER/PR-positive,
HER2-positive mBC (46:40)
Investigation of other strategies designed to exploit the
PI3K/AKT/mTOR pathway (50:06)
Early activity and safety data with the use of CDK4/6
inhibitors as neoadjuvant therapy; ongoing evaluation and potential
clinical role (51:08)
Perspectives of Dr Burstein and Dr Love on the passing and
legacy of the breast cancer revolutionary Dr Bernard Fisher
(56:40)
Advances in the adjuvant treatment of HER2-positive and
triple-negative breast cancer (1:02:24)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.